NB-4746 (Dose TBD)
Preclinical
NB-4746 (Dose TBD) is one of 5 therapeutic programs targeting Amyotrophic Lateral Sclerosis (ALS). It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
4
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
6 competitors in Amyotrophic Lateral Sclerosis (ALS)
#DrugCompanyPhaseTrials
1VHB937
NovartisPhase 2
ALN-SOD
RegeneronPreclinical
NB-4746 Low Dose
NNura Bio
Preclinical
MTP-101C
UUniversity of Minnesota
Preclinical
NB-4746 (Dose TBD)
NNura Bio
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for NB-4746 (Dose TBD). EMBL-EBI & Wellcome Sanger Institute.
- [3]